Ask a serious retail investor to describe how they research a stock and you'll get something like this:
- Run a screen on Finviz to find candidates
- Open TradingView to look at the chart
- Open Macrotrends or a similar site for 5–10 years of financial history
- Open the company's investor relations page, or SEC EDGAR, to pull the latest annual report
- Open a news aggregator to see what's happened recently
- Optionally: open a third site for analyst estimates, a fourth for insider transactions
That's five to seven tools, five to seven browser tabs, five to seven context switches — to evaluate a single stock that may take three minutes to dismiss.
This is the workflow that most investors have built not because it's good, but because no single tool covered everything they needed. Each tool solved one piece of the problem. The investor became the integration layer.
Why the fragmented workflow exists
The fragmentation isn't accidental. It's the result of different tools being built for different primary purposes:
Finviz was built as a screener. It's excellent at filtering stocks by criteria, but it's not a research tool. It gets you to a shortlist; it doesn't help you evaluate anything on that shortlist.
TradingView was built as a charting platform. The screener is a feature added to a charting tool, not the other way around. For chart-driven analysis, it's best-in-class. For fundamental research, it's shallow.
Macrotrends, Wisesheets, and similar tools were built to surface historical financial data. They do that well. They weren't built to integrate with a screening workflow.
SEC EDGAR and filing aggregators surface primary documents. They're archives, not analysis tools.
Each tool is good at its job. The problem is that none of them are designed to be part of a workflow. They're silos. The investor connects them manually, every time, for every name.
What the fragmentation costs
The obvious cost is time. If evaluating each screener result takes five tool switches before you can decide whether it's worth investigating further, you'll evaluate fewer stocks per session and spend more time on administrative tasks than on actual judgment.
The less obvious cost is context loss.
When you move from Finviz to TradingView to Macrotrends, you're rebuilding context each time. You're re-locating the stock, re-orienting to the interface, and re-loading the mental model you built in the previous tool. That cognitive overhead compounds across a research session. You end up spending more energy on navigation than on thinking.
The subtlest cost is consistency. When metrics come from different sources with different methodologies, definitions, and time periods, they're not directly comparable. One tool uses trailing twelve months for margins; another uses the most recent fiscal year. One calculates EV/EBITDA including operating leases; another doesn't. These discrepancies are small enough to ignore in casual research but significant enough to matter in systematic screening.
The problem is worse for European stocks
The fragmented workflow for US stocks is annoying. For European stocks, it's nearly broken.
Finviz doesn't cover European exchange listings. TradingView's fundamental data for European mid and small caps is inconsistent. Historical data sites have patchy coverage outside the largest European markets. Filing aggregators mostly surface SEC documents, not filings from European regulators.
European investors building a systematic workflow often can't get all the components to work at all. The screening step fails because the screener doesn't have the stock. The charting step works. The fundamental research step fails because the data is incomplete or missing. The filing step requires going to each country's exchange website individually.
The result is a workflow that's more broken than fragmented — one where entire steps simply don't execute.
What a coherent workflow looks like
A stock screening and research workflow should have three connected stages:
Stage 1: Filter. Apply criteria to a universe of stocks and surface a shortlist. This requires fast, flexible filtering across all relevant metrics. Results update instantly. The result is a ranked list of candidates.
Stage 2: Orient. For each candidate, get an immediate sense of its profile: what sector, what size, what the key metrics look like, what the price history shows. This stage should take thirty seconds per stock and tell you whether to proceed or skip.
Stage 3: Evaluate. For candidates that pass the orientation stage, go deeper: multi-year financial trends, recent news, balance sheet details, valuation context. This is where judgment happens.
The fragmented workflow collapses stages 2 and 3 into a five-tool process that should take thirty seconds and instead takes ten minutes. Tools that integrate these stages meaningfully make better use of an investor's time.
What ScreenerHero addresses
ScreenerHero is built around the screening and orientation stages, with a particular focus on European stocks — the part of the workflow that is most broken for most tools.
The screener covers 17,000+ stocks across the US, Canada, and European markets — including XETRA, Euronext Paris, BME, and Borsa Italiana — with fundamental filters applied consistently. You filter by P/E, margin, debt, yield, and performance. Results appear instantly.
The stock profile gives you what you need for orientation: key fundamentals, sector context, price history, and ranking within its peer group. The goal is to answer the filter-or-proceed question in the thirty seconds it should take, without switching to another tool.
This doesn't replace the evaluation stage — deep research on a specific investment still requires primary sources, judgment, and often tools specialized for that analysis. But it compresses the stages that shouldn't take as long as they do, for the part of the market that has the fewest tools designed for it.
The question worth asking
If your current research workflow requires five tabs and fifteen minutes to decide whether a stock is worth a closer look, the cost isn't just the fifteen minutes. It's every stock you didn't look at because the friction made it not worth starting.
The best workflow is the one you'll actually run consistently. Consistent, systematic screening — even with simpler criteria — produces better outcomes than intermittent, thorough research done only when motivation is high.
Reducing the friction doesn't just save time. It changes how often you show up.
Frequently asked questions
What tools do professional investors use for stock screening?
Professional investors typically use Bloomberg Terminal ($24,000/year), FactSet ($15,000+/year), or Refinitiv for broad coverage and institutional data. Individual investors with smaller budgets use tools like Finviz Elite, TIKR Pro, Koyfin, Stockopedia, or ScreenerHero — which replicate the core screening workflow at retail prices. The institutional tools add features like earnings call transcripts, order flow data, and portfolio analytics that most individual investors don't need.
Why is the US stock research workflow better supported than Europe?
US financial markets are larger, more liquid, and more institutionally traded than European ones — which means more data providers, more coverage, and more tool investment. European markets are a patchwork of 14+ national exchanges with different languages, currencies, regulatory frameworks, and data formats. Building the data infrastructure to cover them properly is significantly harder than covering NYSE and NASDAQ, which is why most tools do it poorly.
What is the minimum viable stock research workflow?
The most efficient minimal workflow has three tools: a screener to generate candidates (Finviz for US, ScreenerHero for European and global coverage), a financial data site for multi-year statement history (TIKR or Stock Analysis), and a broker with access to annual reports. Everything beyond this — charting platforms, news aggregators, alternative data — adds incremental value but is optional for a fundamentals-based approach.
How many stocks can you realistically research per week?
An individual investor doing serious research can typically evaluate 5–15 stocks per week at a "deserve a closer look" level — checking the screener output, reading recent results, checking the balance sheet and valuation context. The initial filter-or-skip decision, if the workflow is efficient, should take 2–3 minutes per stock. Deep research — reading several annual reports and building a thesis — takes 2–8 hours per company, limiting most investors to 1–3 thorough evaluations per week.
Does reducing tool fragmentation actually improve investment returns?
Not directly — but it removes a barrier that prevents consistent screening. The research shows that consistent, systematic application of a simple strategy outperforms intermittent application of a sophisticated one. The friction of a five-tool workflow is a real barrier to consistency. Investors who only research stocks when they have two hours and high motivation will research less frequently than investors whose workflow takes thirty minutes. Frequency and consistency matter more than sophistication.
Open ScreenerHero → — screen and orient in the same tool, free, no account required. US, Canada, and all European exchanges. Pro at $29/month.